Immuno-oncologic profiling of pediatric CNS tumors reveals major clinical significance of the tumor immune microenvironment
Authors:
Preprint
- 21 March 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
With the increasing use of immunotherapy in cancer, understanding the tumor immune microenvironment (TIME) has become increasingly important. There has been great success in treatment of some pediatric high-grade gliomas with immune checkpoint inhibition, however overall, the immune microenvironment in pediatric brain tumors remains poorly understood. Accordingly, we developed a clinical immune-oncology gene expression assay and used it to profile a diverse range of pediatric brain tumors with detailed clinical and molecular annotation, including a total of 1379 cases. Our findings demonstrate the critical importance of understanding the TIME to guide the prognosis and management of pediatric brain tumors. In pediatric low-grade gliomas we identified distinct patterns of immune activation with prognostic significance in BRAF V600E mutant tumors. In pediatric high-grade gliomas, we observed elevated inflammation and T cell infiltrates in tumors that have historically been considered immune cold, as well as genomic correlates of inflammation levels. In our cohort of mismatch repair deficient high-grade gliomas treated with immune checkpoint inhibition, we found that high tumor inflammation signature was a significant predictor of treatment response. Furthermore, we demonstrated the potential for multimodal biomarkers to improve the treatment stratification of these patients. Importantly, while overall patterns of immune activation were observed for histologically and genomically defined tumor types, there was nonetheless significant variability within each diagnostic entity, indicating that the immune response must be evaluated as an independent feature. In sum, in addition to the histology and molecular profile, this work establishes the importance of assessing and reporting on the tumor immune microenvironment as an essential axis of cancer diagnosis in the era of personalized medicine.Keywords
All Related Versions
- Version 1, 2023-03-21, Research Square
- Published version: Nature Communications, 15 (1), 1.
This publication has 53 references indexed in Scilit:
- Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline gliomaEBioMedicine, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesCell, 2020
- Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading LeukocytesCell, 2020
- Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune CellsCell, 2020
- Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade GliomasCancer Cell, 2020
- cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutationActa Neuropathologica, 2019
- Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized TrialCancer Cell, 2018
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyThe Lancet, 2018
- Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell responseJournal of Neuro-Oncology, 2018